Rithish

Assoc Editor-In-Chief @WikiDoc | PGY-1 Resident Physician @onebklynhealth | Former GI-Onco research Asst @MaimoHealth | GI cancers | @IMRC_Team | Bongos |

[Rithish @RithishNim]

Link - https://t.co/IqnLcnXEQl

[Rithish @RithishNim]

🚨 Excited to share our latest publication on ECMO anticoagulation!

The ECMO landscape is shifting toward precision-based, individualized anticoagulation strategies that integrate In this review, we aimed to consolidate the evolving evidence into one comprehensive resource.

[Rithish @RithishNim]

@nekuendhukuraa Nah changed completely, that study is with Satwik under review still

[Rithish @RithishNim]

Another this week.! 1 year of patience and hustle finally paid off .!

#Haematology

[Keith Siau @drkeithsiau]

😅

[Matheus Alves @mathalveslim]

Saindo do forno! 🔥

Apixabana ou rivaroxabana para tratar TEV agudo? Ambos são DOACs amplamente utilizados, mas nunca haviam sido comparados em um RCT.

O estudo COBRRA (NEJM 2026) tentou responder uma pergunta clinicamente relevante:

➡️ Qual deles causa menos sangramento?

[Rithish @RithishNim]

Such a welcoming and timely update to share during #CRCAwarenessMonth!

Let’s continue raising awareness for colorectal cancer prevention and early detection. 💙

#Colorectalcarcinoma

[OncoDaily GI @OncoDailyGI]

ImmunoXXL Phase II Study: Liver Transplantation After Atezolizumab–Bevacizumab Downstaging in Advanced HCC

In a prospective study, 16 patients with intermediate and advanced HCC beyond extended transplant criteria were downstaged with Atezo–Bev and underwent liver transplantation.

Key outcomes
• 2-year RFS: 90%
• 2-year OS: 94%
• Acute rejection: 25%

The authors conclude that liver transplantation should be considered after HCC response to immunotherapy.

@DJPinato @MariannaMaspero @MarcoBongini

https://t.co/U9e3y8w6pP

#HCC #LiverCancer #Immunotherapy #TransplantOncology #Oncology

[Neil Stone @DrNeilStone]

Vaccines don't cause autism

[Rithish @RithishNim]

Shoutout to @MTANewsroom @MTA for relentless services today across NYC amidst the #blizzard kudos @NYCMayor

Still able to take a bus on time 🙌🏻

[Rithish @RithishNim]

@RiddhiMachchhar @ebmedgi @SpringerNature @HMHNewJersey @RowanVirtuaSOM @ScrubsNHeels Kudos 🙌🏻

[Rithish @RithishNim]

@mystic_swoop @ASCO 🙌🏻

[Rithish @RithishNim]

Another cancer presentation on the way

This time in my niche of colorectal cancer. Looking forward to learning, sharing insights, and connecting with peers from similar backgrounds.

📍 Chicago - May

#Colorectal @ASCO

[Rithish @RithishNim]

@GiOncNow @OncoDailyGI

[Rithish @RithishNim]

New Study of ours is out now🚨.!

Key Insight from Our Recent Meta-Analysis: CRC in Solid Organ Transplant Recipients

Please do study and let us know what you think of.! Thank for the amazing team and work display

#oncology #CRC

Link - https://t.co/LcDvcutADq

[GI Oncology Now @GiOncNow]

🧬 In a systematic review presented @ASCO #GI26, researchers found that improved survival outcomes in #BRAF V600E-mutated #metastatic #ColorectalCancer with triplet therapy relative to doublet therapy likely did not justify its use: https://t.co/2XD078Ekbc

[Rithish @RithishNim]

@GiOncNow @ASCO That’s our study .! Thanks for highlighting

[OncoDaily GI @OncoDailyGI]

CAVE-2 GOIM: ctDNA-Guided Anti-EGFR Rechallenge in mCRC

Cetuximab rechallenge ± avelumab in MSS, RAS/BRAF WT mCRC selected by plasma ctDNA.

Results
• OS: 14.8 vs 12.9 mo (HR 1.00)
• PFS: 5.3 vs 4.3 mo (HR 0.78)
→ No benefit from adding avelumab

Key insight
ctDNA “negative hyper-selection” identified patients with longer outcomes:
• OS 15.0 vs 11.1 mo
• PFS 5.35 vs 3.65 mo

@DCiardiello @FilippoPietran4

https://t.co/Gf6Qcb0QSU

#mCRC #ctDNA #LiquidBiopsy #AntiEGFR #PrecisionOncology

[Rithish @RithishNim]

@NicoGagelmann Absolutely

[Om Prakash, MD @ompsychiatrist]

My favorite line to New Resident Doctors:

Don't miss your breakfast.